Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or

Trial Details

NCT ID
NCT07339059
Phase
PHASE2
Sponsor
Bindu R Potugari
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sacituzumab govitecan
  • Atezolizumab
  • Durvalumab
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Participant is willing and able to give informed consent for participation in the trial.
  • Male or Female aged 18 years or above.
  • Participants must have a histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC) and extensive stage at diagnosis or l…
  • Participants must have received at least four cycles of platinum plus etoposide and at least 2-3 cycles of atezolizumab/ Durvalumab.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →